Malaysia Pharmaceuticals & Healthcare Report

Published 29 June 2015

  • 141 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Malaysia Pharmaceuticals & Healthcare Report

BMI View: Despite the decline in oil prices impacting government spending, we believe the Malaysian government will be able to maintain its commitment to the country ' s healthcare sector as it continues diversification of its revenue base. Moreover, healthcare provision remains critical to the government which will limit reductions that affect medical services. However, commercial opportunities for innovative drugmakers continue to be weighed down by low levels of intellectual property protection, the implementation of a Goods and Service Tax (GST) as well as the preferential treatment of local drugmakers.

Headline Expenditure Projections

  • Pharmaceuticals: MYR7.22bn (USD2.21bn) in 2014 to MYR7.88bn (USD2.13bn) in 2015; +9.2% in local currency and -3.4% in US dollar terms.

  • Healthcare: MYR42.75bn (USD13.06bn) in 2014 to MYR46.13bn (USD12.47bn) in 2015; +7.9% in local currency and -4.6% in US dollar terms.

Risk/Reward Index

Malaysia's Pharmaceutical Risk/Reward Index (RRI) score for Q315 is 58.9 out of 100, making it the eighth most attractive pharmaceutical market in the Asia Pacific region. It posts above-average scores for every indicator.

Key Trends And Developments

May 2015

  • A total of 16 health infrastructure improvement projects, worth MYR2.3bn (USD644.7mn), will be implemented across the Malaysian state of Johor under the 11th Malaysia Plan (11th MP), reports Bernama. The proposal for the projects, which includes the construction of the new Pasir Gudang hospital and Sultanah Aminah 2 hospital in Tampoi, have been submitted to the Economic Planning Unit for consideration, according to State Health and Environment Committee Chairman Ayub Rahmat. The construction of new hospitals and health clinics under the 11th MP will be carried out by a collaborative effort between the state government and the health ministry. The state government is also proposing to upgrade the Segamat hospital to a specialist hospital as well as building health clinics in Rengit,...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
13
Operational Risk
15
Industry Forecast
17
Pharmaceutical Market Forecast
17
Table: Pharmaceutical Sales, Historical Data And Forecasts (Malaysia 2011-2019)
19
Healthcare Market Forecast
20
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2011-2019)
22
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2011-2019)
22
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2011-2019)
23
Prescription Drug Market Forecast
24
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Malaysia 2011-2019)
25
Patented Drug Market Forecast
26
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Malaysia 2011-2019)
28
Generic Drug Market Forecast
29
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Malaysia 2011-2019)
31
OTC Medicine Market Forecast
32
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Malaysia 2011-2019)
34
Pharmaceutical Trade Forecast
35
Table: Pharmaceutical Trade Data And Forecasts (Malaysia 2013-2019)
37
Table: Pharmaceutical Trade Data And Forecasts local currency (Malaysia 2013-2019)
38
Key Risks To BMI's Forecast Scenario
39
Macroeconomic Forecasts
41
Economic Analysis
41
Headwinds To Curtail Growth
42
Infrastructure The Sole Bright Spot
43
Table: Economic Activity (Malaysia 2010-2019)
44
Industry Risk Reward Ratings
45
Asia Pacific Risk/Reward Index
45
Malaysia Risk/Reward Index
51
Rewards
51
Risks
51
Market Overview
53
Industry Trends And Developments
54
Epidemiology
54
Healthcare Sector
56
Table: 2011 Entry Point Projects Summary
58
Table: Healthcare Resources (2009-2014)
59
Table: Healthcare Activity (2009-2014)
59
Table: Healthcare Personnel (2009-2014)
59
Healthcare Insurance
60
Table: Main Features Of 1Care
60
Healthcare Funding
62
Healthcare Sector Developments
63
Table: Public Sector And Private Sector Healthcare Developments
63
Medical Tourism
64
Research & Development
65
Clinical Trials
67
Regulatory Development
70
Regulatory Regime
70
Table: Drug Applications by Type, 2002-2010
72
Table: Registered Pharmaceutical Products by Type, 2002-10
72
Regulatory Developments
73
Intellectual Property Issues
77
Pricing Regime
82
Competitive Landscape
84
Domestic Industry
84
Foreign Industry
86
Table: Leading Malaysian Pharmaceutical And Healthcare Companies
88
Culture-Specific Medicines
89
Pharmaceutical Distribution
91
Table: Drug Wholesalers & Importers, 2002-2010
92
Pharmaceutical Retail Sector
92
Company Profile
94
Bumimedic
94
Kotra Pharma
96
Pfizer
99
Pharmaniaga
102
Prime Pharmaceutical
106
Hovid
108
Chemical Company Of Malaysia
111
GlaxoSmithKline
115
Novartis
118
Merck & Co
121
Sanofi
124
Eli Lilly Malaysia
126
Ranbaxy Malaysia
128
Demographic Forecast
130
Table: Population Headline Indicators (Malaysia 1990-2025)
131
Table: Key Population Ratios (Malaysia 1990-2025)
131
Table: Urban/Rural Population & Life Expectancy (Malaysia 1990-2025)
132
Table: Population By Age Group (Malaysia 1990-2025)
132
Table: Population By Age Group % (Malaysia 1990-2025)
133
Glossary
135
Methodology
137
Pharmaceutical Expenditure Forecast Model
137
Healthcare Expenditure Forecast Model
137
Notes On Methodology
138
Risk/Reward Index Methodology
139
Index Overview
140
Table: Pharmaceutical Risk/Reward Index Indicators
140
Indicator Weightings
141

The Malaysia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Malaysia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Malaysia pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Malaysia, to test other views - a key input for successful budgeting and strategic business planning in the Malaysian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Malaysian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Malaysia.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc